Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers

Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects

(2013) M Ulvestad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors

(2012) Tatiana F.S. Teixeira et al.   CLINICAL NUTRITION

Impact of Obesity on Drug Metabolism and Elimination in Adults and Children

(2012) Margreke J.E. Brill et al.   CLINICAL PHARMACOKINETICS

Morbid obesity rates continue to rise rapidly in the United States

(2012) R Sturm et al.   INTERNATIONAL JOURNAL OF OBESITY

Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters

(2011) Romi Ghose et al.   LIFE SCIENCES

Development of a Population Pharmacokinetic Model for Taranabant, a Cannibinoid-1 Receptor Inverse Agonist

(2010) Xiujiang (Susie) Li et al.   AAPS Journal

Obesity, Inflammation, and Cardiovascular Risk

(2010) P Mathieu et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Obesity Affects the Liver – The Link between Adipocytes and Hepatocytes

(2010) Alexander Wree et al.   DIGESTION

Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes

(2010) Jian Yang et al.   TOXICOLOGY LETTERS

Population-Based Mechanistic Prediction of Oral Drug Absorption

(2009) Masoud Jamei et al.   AAPS Journal